Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM): an updated analysis based on 14-month follow-up data
Hans C. Lee, MD
Associate Professor & Director, Multiple Myeloma Clinical Research
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Houston, Texas, United States